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Several reports in the literature have drawn a complex picture of the effect of treatments
aiming to modulate IL2 activity in vivo. They seem to promote either immunity or toler-
ance, probably depending on the specific context, dose, and timing of their application.
Such complexity might derive from the pleiotropic role of IL2 inT cell dynamics.To theoret-
ically address the latter possibility, our group has developed several mathematical models
for Helper, Regulatory, and Memory T cell population dynamics, which account for most
well-known facts concerning their relationship with IL2. We have simulated the effect of
several types of therapies, including the injection of: IL2; antibodies anti-IL2; IL2/anti-IL2
immune-complexes; and mutant variants of IL2. We studied the qualitative and quantita-
tive conditions of dose and timing for these treatments which allow them to potentiate
either immunity or tolerance. Our results provide reasonable explanations for the existent
pre-clinical and clinical data, predict some novel treatments, and further provide interesting
practical guidelines to optimize the future application of these types of treatments.
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INTRODUCTION
Several reports in the literature have drawn a complex picture of
the effect of treatments aiming to modulate IL2 activity in vivo.
These treatments seem to promote either immunity or tolerance,
probably depending on the specific context, dose, and timing of
their application.
Treatments that increase IL2 activity, simply by injecting it,
have been shown to potentiate the immune response to vaccines
(1–4) and are a current medical practice to enhance the nat-
ural anti-tumor immunity in patients with melanoma. However,
several reports in the literature have shown that HIV (5–8) and
melanoma (9) patients treated with IL2, experience an increase in
CD4+ CD25+ FoxP3+ regulatory T cells, which typically mediate
natural immune tolerance. Moreover, several pre-clinical studies
have further documented a tolerogenic effect of IL2. Injections
of IL2 have been shown to prevent or ameliorate autoimmune
responses in mice (10–12). Treatments which reduce natural IL2
activity, by sequestering it with anti-IL2 monoclonal antibodies,
have been shown to induce autoimmune responses (13). And
treatments intending to block IL2 activity, with non-depleting
anti-IL2-receptor antibodies, are showed to have anti-tumoral
effects (14). Nevertheless, in the clinical practice non-depleting
anti-IL2-receptor antibodies are used to ameliorate the autoim-
mune reaction in patients with neoplasia, autoimmune diseases,
and organ allograft rejection (15).
Further complexity to the latter picture has been recently added
with the pre-clinical assessment of treatments based on immune-
complexes formed by IL2 and monoclonal antibodies anti-IL2.
This treatment shows a much more potent in vivo effect than IL2
alone, appears again to potentiate either immunity (16, 17) or tol-
erance (18), depending on the specific antibody used to form the
immune-complexes. In particular, the specific epitope in the IL2
recognized by the antibody has been postulated as critical for this
phenomenon (19, 20).
IL2 interacts with many different cells types, which express the
three known chains of the IL2 receptor. Particularly relevant and
complex is its relationship with the population dynamics of the
CD4 T lymphocytes. IL2 was originally described as a potent CD4+
T cell growth factor (21), which should in consequence enhance
overall T cell immunity. However, several experiments have shown
lately a critical role for this cytokine in the survival and prolifer-
ation of the CD4+CD25+FoxP3+ T cells (regulatory T cells) (22,
23), which mediate the maintenance of natural and induced toler-
ance. The CD4+CD25−FoxP3− T cells (helper T cells) have been
identified as the principal source of IL2 in vivo (24), suggesting that
the regulatory T cells have to sequester the IL2 produced by these
cells in order to proliferate and survive (25). Moreover, in vitro
and in vivo experiments have shown that regulatory T cells inhibit
the production of IL2 by the helper T cells (26), limiting in this
way their own source of this essential cytokine. Thus, overall, it
seems that IL2 has a dual role on its circuit of interactions with
CD4+ T cells. It could promote the proliferation of the helper T
cells, which may drive effective immunity and foster IL2 produc-
tion. But, it could also promote the expansion of regulatory T cells,
which may turn off the immune reaction, as well as the IL2 pro-
duction on its own. The dynamic balance between these opposite
forces might explain the complexity observed in the effect of treat-
ments that modulate IL2 activity, either sequestering it or further
increasing it.
To theoretically address the latter hypothesis, our group has
developed mathematical models for Helper, Regulatory, and Mem-
ory T cells dynamics, which account for most well-known facts
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relative to their relationship with IL2. We have simulated the effect
of several types of therapies including the injection of: IL2; anti-
bodies anti-IL2; IL2/anti-IL2 immune-complexes, and mutants
variants of IL2. We studied the qualitative and quantitative con-
ditions of dose and timing for these treatments which allow them
to potentiate either immunity or tolerance. Our results provide
reasonable explanations for the existent pre-clinical and clinical
data, predict some novel treatments, and further provide interest-
ing practical guidelines to optimize the future application of these
types of treatments.
MATERIALS AND METHODS
INTRODUCTION TO THE MATHEMATICAL MODEL
The mathematical model used in this paper is based on the one
developed in Ref. (27) to describe the interaction between IL2 and
helper (E) and regulatory (R) CD4+ T cells and memory CD8+
T cells inside a lymph node. The model includes several physical
compartments, which minimally capture the bio-distribution of T
cells, IL2, and antibodies in the immune system (see Figure 1). It
includes several compartments, which represent different lymph
nodes, where T cells are confined interacting with each other’s,
with the antigen presenting cells (APCs) and available soluble
molecules. It includes also a compartment representing the blood
(i.e., the circulatory system), which contains only soluble mol-
ecules, IL2, mutant variants of IL2 or anti-IL2 antibodies. Each
lymph node in the system is connected to the blood compartment,
allowing the free exchange of these soluble molecules.
DYNAMICS IN THE BLOOD COMPARTMENT
The concentration of soluble molecules in the blood compartment
is assumed to decay with a constant characteristic rate, which rep-
resent renal elimination in the kidney. An external source term
for these molecules is added in this compartment to simulate par-
ticular treatment applications. Interaction between free IL2 and
anti-IL2 antibodies are modeled in this and other compartments
as a dynamic equilibrium characterized by a given biding affinity.
Equations for the dynamics in this compartment are presented in
“Dynamics in the Blood Compartment” in Appendix A.
DYNAMICS FOR T CELLS INSIDE LYMPH NODES
The model includes, inside the lymph nodes, the dynamics of
Helper (E), and Regulatory (R) T cells on three different func-
tional states of their life cycle: resting, activated, and cycling cells.
All the interactions involving these T cells occur in the presence
of a constant amount of their cognate APCs and relevant homeo-
static cytokines. The basic processes and interactions included in
the model dynamics for these T cells are (see Figure 2 and (27, 28)
for a more detailed biological explanation, including references to
experiments that sustained their validity):
i. Resting E and R cells are produced at constant rate by the thy-
mus; they die with a constant decay rate; they get activated
(becoming an activated cell) following conjugation to their
cognate APCs. The activation of E cells can be inhibited by the
presence of co-localized R cells on the APCs.
ii. The activated E and R cells could become cycling cells fol-
lowing a dose-dependent response to cytokine derived signals.
The activated R cells get this signal from the interaction with
available IL2 while the E cells could additionally use other
homeostatic cytokines1, which are referred in the model as
1Note that, although other cytokines are able to stimulate Tregs in vitro, several
reports in the literature have indicated IL2 as the key cytokine for the proliferation
FIGURE 1 | Diagram of the processes occurring in the two
compartments considered in the model. At the left side of the diagram
the blood compartment is shown, where soluble molecules related with
IL2 modulatory therapies are introduced and eliminated. This compartment
is in constant molecular exchange with the lymph nodes (right side of the
diagram). In this last class of compartment, occur the processes related
with the dynamics of T cells and their interaction with the IL2 and other
soluble molecules.
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FIGURE 2 | Diagrams of helper (E), regulatory (R), and memory (M)T-cell
life cycle considered in the model. New resting E (EN) and R (RN) cells are
constantly generated by the thymus. These resting T cells become activated
by interaction with their cognate APCs. During activation, E cells produce IL2,
although the whole process can be inhibited by the presence of co-localized R
cells. Activated E (EA) and R (RA) enter the cell cycle (becoming cycling cells)
when receiving enough signal from IL2 or another external cytokine (IL-α) in
the case of E cells. In the absence of enough cytokines, activated T cells
become inactivated, where a fraction of cells simply returns back to the
resting state and the other dies. Cycling E (EC) and R (RC) cells divide with a
constant rate generating two new resting E or R cells, respectively. Memory T
cells are assumed as being always in a sort of naturally activated state (even
without any strong cognate interaction with APCs). Activated M (MA) cells
enter the cell cycle when receiving enough signals from IL2 or another
external cytokine (IL-m). Cycling M cells (MC) divide generating two new
activated M cells.
ILa and are available inside the lymph node in a constant but
limited amount. In the absence of enough cytokine derived
signal, a fraction of the activated E or R cells revert to the
resting state and the remaining fraction just die.
iii. The cycling E and R cells are fully committed to divide, pro-
ducing two new resting cells. Thus, they are presumed to do
so with a constant rate.
The model includes also the dynamics of a generic population
of non-CD4 T cells, which binds weakly to the existent APCs, but
proliferates in response to IL2 signal, with similar sensitivity than
the activated helper CD4+ T cells. This cells (referred as M cells)
represent, the memory CD8+CD44+ T cells, which can prolifer-
ate in response to IL2 without any requirements of activation by
cognate APCs (see Figure 2).
The dynamics of the number of T cells in the lymph node
compartment, following the process described above, are modeled
and survival of Treg cells in vivo. The group of Freitas (24) have shown that the
absence of CD4+ T cells capable of producing IL2, leads to the absence of Treg
cells and to the development of autoimmunity. Moreover, mice knockouts of IL2
or IL2 receptor components have been shown to lack the accumulation of Tregs
in vivo, exhibiting once more an autoimmune phenotype (48, 49). Interestingly in
these latter scenarios of autoimmune mice, other cytokines besides IL2 are capable
to maintain and expand the auto-reactive helper CD4+ T cells (perhaps IL7, IL15,
or IL21).
with the set of equations presented in “Dynamics of T Cells in the
Lymph Node Compartment” in Appendix B.
DYNAMICS IL2 AND ANTIBODIES ANTI-IL2 INSIDE THE LYMPH NODE
The dynamics of IL2 molecules inside the lymph node takes into
account the role of T cells in the production and degradation of
this cytokine. The following processes are considered in the model
[see Figure 2 and Ref. (27) for a more detailed biological expla-
nation, including references to experiments that sustained their
validity]:
iv. IL2 is produced by E cells upon activation. It is produced
as a burst whenever a resting E cell becomes an activated E
cell. Such production of IL2 is inhibited, together with the E
cell activation, by the presence of co-localized R cells on the
APCs.
v. IL2 is degraded in the lymph nodes, after being internalized
by the T cells in the form of complexes with the IL2 receptor
at their cell surface.
Interactions of IL2 and T cells in the model are based on
the expression by these cells, either in the resting, activated
or cycling state, of different levels of the IL2 receptor. These
receptors mediate the binding of IL2, which provide a stim-
ulatory signal in a dose-dependent fashion to the T cell. In
this model the three known chains of the IL2 receptor, alpha,
beta, and gamma (29) are included. These three chains are
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combined dynamically at the cell surface, upon IL2 binding,
to conform the two known signaling forms of the IL2 recep-
tors. The following processes and known facts are considered
in the model regarding this interaction [see Figure 3 and
Ref. (27)]:
vi. IL2/IL2Receptor complexes formation is modeled as a multi-
step process: free, soluble, IL2 binds initially to the available
free alpha or free beta chains of the receptor, and only then
can form dimers or trimers with the remaining IL2 receptor
chains at the cell membrane. The gamma chain is assumed
to be always in excess compared with the amount of beta
chain bound to IL2, either alone or together with alpha
chain. Therefore gamma chain joins immediately to these
membrane complexes, forming the well known intermediate
(beta-gamma-IL2) or high affinity (alpha-beta-gamma-IL2)
IL2–IL2 receptor complexes.
vii. IL2/IL2Receptor configurations, which include the beta and
gamma chains (high-affinity alpha-beta-gamma, and inter-
mediate affinity beta-gamma receptor), trigger a signal into
the T cells (19). Therefore, in the model, the mean number
of such signaling receptors per activated E cell, R cell, and
M cell are counted. Then, the probability of getting enough
signal as to become a cycling cell, for any particular activated
E, R, or M cell, is computed with a sigmoid dose response
curve, of the mean signaling level. The use of a sigmoid dose
response curve is based on direct experimental observations
on in vitro culture of CD4+ T cells (30) stimulated with
recombinant IL2.
viii. Beta and gamma chain of the IL2 receptor are similarly
expressed by E and R cells in all functional states, but the
expression of the alpha chain is modulated with T cell acti-
vation (31). R cells constitutively express the alpha chain in
the resting state, but further increase its expression level with
activation. E cells do not express the alpha chain in the resting
state, but gain a significant expression level with activation.
ix. The M cells are assumed to express a negligible amount of
the alpha chain of IL2 receptor, but have levels of the beta
and gamma chain which are higher than those of helper and
regulatory T cells (32).
Antibodies anti-IL2 are modeled as molecules that can form
complexes with the IL2, blocking or not its binding to the differ-
ent chains of the IL2 receptor at the T cell surface. IL-2 mutants
are modeled as a molecule bearing similar properties than wild-
type IL-2, but differing in some specific parameter value on each
case. In particular, we simulate the effects of IL2 mutants with an
either reduced or increased Kon for the alpha or beta chains of
the IL2R.
The equations in the model describing the dynamics of the
number of molecules circulating in the Lymph Node (IL2, anti-IL2
FIGURE 3 | Interactions between IL2 andT cells in the model are
mediated by the IL2 receptor (IL2R), which is formed by three chains:
alpha, beta, and gamma chain. These chains are combined dynamically in
multi-step process at the cell surface, upon IL2 binding, to conform the two
known signaling forms of the IL2 receptors: high affinity alpha-beta-gamma
and intermediate affinity beta-gamma receptor. In the model, the mean
number of such signaling IL2-IL2R complexes per activated T cell are counted,
and the probability of becoming a cycling cell is computed with a sigmoid
function of the mean number of bound cytokines signaling receptors per cell
(as shown at the right side of the arrow).
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antibodies, and immune-complexes) and the number of com-
plexes IL2-IL2R and IL2-mAb-IL2R formed in a single cell mem-
brane are described in “Dynamics of Molecules in the Lymph
Node” in Appendix C.
SIMULATION OF DIFFERENT THERAPIES
Four types of treatments are simulated in the model: injections
of IL2; injections of anti-IL2 monoclonal antibodies; injections of
immune complex composed of a mixture of IL2 and anti-IL2 anti-
bodies with a specified constant proportion of them; and injection
of mutant variants of IL2.
Treatments are simulated to represent a continuous infusion
of the involved molecules for a defined period of time. This is
implemented by setting on, transiently, the external source term
of the molecules involved in a specific treatment (i.e., IL2; IL2m;
and/or anti-IL2 antibody). Two parameters always control treat-
ment application: the “dose,” which set up the total amount per
day of IL2, IL2m, and/or anti-IL2 antibody infused; and the “treat-
ment duration,” which set the time period for which continuous
infusion is maintained. In all cases, we explore how the dose and
treatment duration determine the outcome of the system simula-
tion. We study whether or not different treatments can condition
a significant preferential expansion (dominance) of helper T cells
or regulatory T cells or M cells in the system.
PARAMETER AND VARIABLE VALUES IN MODEL SIMULATIONS
Model parameters were previously calibrated in Ref. (27). The
actual values of parameter used in our simulations are provided
in Tables 1–3. The majority of the model parameters are fixed
to values directly taken or derived from available independent
experimental data; just a few parameters remain unknown, and
their influence in result was explored inside a range of biologi-
cally reasonable values. Given the realistic values and units of the
most model parameters used in the simulations, we report in this
paper the values of treatments doses in milligrams and the values
of treatment duration in weeks. However, the reader should note
that our model is only roughly calibrated, thus one should believe
on the order of magnitude and general qualitative trends of the
predicted effects. But, the exact values of dose and treatment dura-
tion reported here to cause a given effect in the simulations should
not be taken as a solid prediction.
The simulations of the model dynamics was implemented using
the program Mathematica v.4.0.
RESULTS AND DISCUSSION
BASIC MODEL AND SIMULATIONS SETUP
The model is setup to study the basic homeostasis of the immune
system of a mouse (27). Therefore the APCs in the model are
interpreted as those APCs, which present self-antigens to T cells
in the absence of infections. In consequence, the CD4+ T cells in
the model are taken to represent the populations of auto-reactive E
and R cells, which significantly recognizes the existent self-antigens
and thus interact with the available APCs.
Two main problems are then studied in the model simula-
tions. (a) The basic dynamics states of the system in the absence
of treatments; and (b) The effect of perturbations which repre-
sent specific IL2 modulation treatments on the stability of these
dynamics states.
TOLERANCE AND IMMUNITY AS THE BASIC MODEL STEADY STATES
(IN THE ABSENCE OF TREATMENT)
The model has two stable steady states which can be interpreted
as natural tolerance and autoimmunity in the system. The steady
state, which is interpreted as an autoimmune state (Figure 4A),
is one where auto-reactive helper cells are significantly expanded
while the auto-reactive Regulatory T cells are outcompeted from
their cognate APCs. This steady state is also characterized by
the existence of high levels of free IL2 and some subsequence
expansion of the memory CD8+ T cells population (M cells) in
the lymph nodes. The steady state, which is interpreted as nat-
ural tolerance in the model, is one where the auto-reactive E
and R cells co-exist in a dynamic equilibrium (Figure 4B). In
this steady state the expansion of the auto-reactive helper cells is
actively controlled by their interaction with the auto-reactive Reg-
ulatory T cells, the amount of free IL2 remains very low and the
size of M cell population remains close to its basal homeostatic
level.
A key dynamical property of the model is the existence of
a parameter regime where these steady states of tolerance and
autoimmunity can co-exist. This is a regime of bistable behav-
ior (Figure 4C), where the model could evolve dynamically into
either to the autoimmune or the tolerant steady state, but depend-
ing on the initial conditions used to seed the simulation without
any change of parameter values (i.e., changing the initial propor-
tion of auto-reactive E to R cells). The model is set to operate
inside this bistable parameter regime. Thus in equilibrium, in the
absence of treatments, the system will be either in the tolerant
or the autoimmune steady state referred above. Such parameter
choice is required to explain properly with the model the results
of adoptive transfer experiments in mice, where transferring dif-
ferent proportions of CD4+CD25− (helper) and CD4+CD25+
(regulatory) T cells into immune deficient mice (those lacking T
cells, Rag−/− or nu−/−), they either reconstitute a normal (toler-
ant to self-antigens) immune system or develop an autoimmune
disease mediated by the uncontrolled expansion of the transferred
auto-reactive CD4+ T cells (28).
Moreover, it is important to note that the model reviewed here
is an extension of the cross-regulation model of immunity, which
studies the interaction of helper and regulatory CD4+ T cells in
the lymph node of the normal mice (33). Interestingly, despite of
substantial increase on the number of variable and parameters, the
new model conserves the three main dynamical properties of the
original one reviewed in Ref. (34). In Ref. (28), three parameter
conditions were presented as necessary in the extended model to
behave as the original model and therefore to explain the same
phenomenology. These conditions are:
(1) Regulatory T cells have to be more efficient using IL-2 at low
concentrations than helper and memory T cells.
(2) The existence of a cytokine alternative to IL-2 that promote
helper T cell proliferation and survival.
(3) The helper cells must become activated and proliferate more
rapidly than Regulatory T cells in conditions of IL-2 excess.
A detailed discussion of the validity of these constrains, from
an experimental point of view, is provided in Ref. (28).
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Table 1 | Variables and parameters appearing in the equations that model the dynamics in the blood compartment.
Variables Definitions
IL2S Total number of IL2 molecules in the blood
IL2mS Total number of IL2m molecules in the blood
AbS Total number of anti-IL2 mAb in the blood
IL2AbS Total number of IL2-mAb complexes in the blood
IL2 Total number of free IL2 molecules (non-conjugated to IL2R at the cell membrane) in the lymph node
IL2m Total number of free IL2m molecules (non-conjugated to IL2R at the cell membrane) in the lymph node
Ab Total number of free anti-IL2 mAb (non-conjugated to IL2-IL2R complex at the cell membrane) in the lymph node
IL2Ab Total number of free IL2-mAb complexes (non-conjugated to IL2R at the cell membrane) in the lymph node
Symbolic labels Definitions
j Symbolic label that denotes the different IL2R chains: j = α (alpha chain) and j = β (beta chain)
l Symbolic label that denotes the possible functional states of the T cells: l =N resting state, l =A activated state and l =C cycling state
Parameters Definitions Values used in simulations
Γi External influx of IL2, typically used to simulate IL2 addition treatment –
K pi Rate of IL2 production by helper CD4+ T cells upon activation 103 M/h
K di Elimination rate of IL2 in the blood Ln(2)/10 min
NLN Total number of equivalent lymph nodes considered in the system 10
D il, Dab Diffusion rate for the exchange of IL2 and mAbs, between the blood and peripheral lymph nodes 10−7 L × Ln(2)/10 min
V S, V LN Volume of the blood and lymph node compartments, respectively 2.5×10−3 L, 10−6 L
fve Fraction of the lymph node volume, in which molecules and mAbs can diffuse 0.1
KAbon ,K
Ab
off Association and dissociation constants of IL2-mAb complexes Face alpha mAb: 1.5×105 M−1s−1,
1.4×10−4 s−1; face beta mAb:
2.3×104 M−1s−1, 6.6×10−5s−1
Γmi External influx of IL2m, typically used to simulate IL2 addition treatment –
Γab External influx of mAb, typically used to simulate anti-IL2 mAbs addition treatment –
Kda Elimination rate of mAbs and IL2-mAbs complexes in the blood Ln(2)/3 days
NA Avogadro’s number 6,02×1023 mol−1
RESPONSE TO TREATMENTS THAT MODULATE IL2 CONCENTRATION
In following sections, the effects of different treatments, which
aim to modulate IL2 activity, are studied. Treatments simulate a
continuous infusion for a defined period of time of the involved
molecules (IL2, IL2m, and/or anti-IL2 antibody). Two parame-
ters control their application: the “dose,” which set up the total
amount per day of IL2, IL2m, and/or anti-IL2 antibody infused;
and the “treatment duration,” which set the time period of sus-
tained infusion. Treatments are always applied in a system which
is initially set to a dynamic equilibrium (i.e., either into the tol-
erant or the autoimmune steady state). We systematically study,
whether a given treatment induces a significant change in the ini-
tial proportion of Regulatory (R) versus Helper (E+M) T cells,
both transiently or permanently. We interpret that a treatment
promotes immunity when it induces a transition from the tolerant
steady state (dominated by R cells) to the autoimmune steady state
(dominated by E cells). We interpret that a treatment promotes tol-
erance when it induces a transition from the autoimmune state to
the tolerant steady state.
Simulating the injection of IL2
Simulations of IL2 injections show that, when this treatment is
applied to a system initialized into the autoimmune steady state,
it is unable to take the system into the tolerant steady state, irre-
spectively of the dose and treatment duration chosen. Moreover,
it further promotes the expansion of the auto-reactive E cells
and the M cells (Figure 5) reinforcing transiently the ongoing
autoimmune response. However, when this treatment is applied
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Table 2 | Variables and parameters appearing in the equations that model theT cells dynamics.
Variables Definitions
EN, EA, EC Total number (conjugated plus non-conjugated) of resting, activated, and cycling E cells
RN, RA, RC Total number (conjugated plus non-conjugated) of resting, activated, and cycling R cells
MA, MC Total number (conjugated plus non-conjugated) of activated and cycling M cells
Intermediate variables Definitions
EBN , E
B
A , E
B
C Number of resting, activated, and cycling E cells conjugated to APCs
EBT Total number of conjugated E cells: E
B
T = EBN + EBA + EBC
EFN, E
F
A , E
F
C Number of resting, activated, and cycling E cells non-conjugated to APCs: E
F
l = El − EBl , ∀l ∈ {N , A, C}
RBN , R
B
A , R
B
C Number of resting, activated, and cycling R cells conjugated to APCs
RBT Total number of conjugated R cells: R
B
T = RBN + RBA + RBC
RFN,R
F
A,R
F
C Number of resting, activated and cycling R cells non-conjugated to APCs: R
F
l = Rl − RBl , ∀l ∈ {N , A, C}
MBA , M
B
C Number of activated and cycling M cells conjugated to APCs
MBT Total number of conjugated M cells: M
B
T =MBA +MBC
MFA , M
F
C Number of activated and cycling M cells non-conjugated to APCs: M
F
l =Ml =MBl , ∀l ∈ {A, C}
F Total number of APC conjugation sites that remain free in the system
SigE, SigR, SigM Number of bound cytokines signaling receptors at the surface of an activated E, R, and M cells
Symbolic labels Definitions
l Symbolic label that denotes the possible functional states of theT cells: l =N resting state, l =A activated state, and l =C
cycling state
Parameters Definitions Values used in
simulations
Γe, Γr Input rate of new resting self-reactive E and R cells from the thymus 2.5×104 cells/day
K EA ,K
R
A Activation rate for resting E and R cells conjugated to APCs Ln(2)/2 h, Ln(2)/6 h
K EP , K
R
P , K
M
P Division rate for cycling E, R, and M cells Ln(2)/4 h
K ES , K
R
S IL2 signaling-waiting rate for activated E and R cells Ln(2)/2 h
KMS IL2 signaling-waiting rate for activated M cells Ln(2)/4 h
K Ed ,K
R
d ,K
M
d Death rate for free resting E and R cells, and free activated M cells Ln(2)/1 week
A Number of total APCs 2×105
s Total number of conjugations site per APC 5
K E, KR Equilibrium conjugation constants (K on/K off) for E and R cells to the APC conjugation sites K on=10−13 L s−1 cell−1,
Koff=6×10−4 s−1
KM Equilibrium conjugation constants (K on/K off) for M cells to the APC conjugation sites K on=10−13 L s−1 cell−1,
Koff=6×10−3 s−1
αE, αR Fraction of activated E and R cells reverting to the resting state in the absence of cytokine
related signal
0.95
h Hill coefficient at the sigmoid response curve 4
SE, SR, SM Sensitivities thresholds for E, R, and M cells to cytokines signal 500
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Table 3 | Variables and parameters related to dynamics of IL2, IL2R, and mAb complexes formation.
Variables Definitions
CElj , C
Rl
j , C
Ml
j Number of IL2 molecules bound to j chain of IL2R, at the surface of the indicated T cell type
CmElj , Cm
Rl
j , Cm
Ml
j Number of IL2m molecules bound to j chain of IL2R, at the surface of the indicated T cell type
CAbElj , CAb
Rl
j , CAb
Ml
j Number of IL2/mAb complexes bound to the j chain of IL2R, at the surface of the indicated T cell type
T El ,T Rl ,TMl Number of IL2 molecules bound to high affinity IL2R (alpha + beta), at the surface of the indicated T cell type
TmEl , TmRl , TmMl Number of IL2m molecules bound to high affinity IL2R (alpha + beta), at the surface of the indicated T cell type
Intermediate variables Definitions
PElj , P
Rl
j , P
Ml
j Number of IL2R of j chain free (not bound to IL2), at the surface of the indicated T cell type
SigE, SigR, SigM Number of cytokines signaling receptors at the surface of an activated E, R, and M cells
Parameters Definitions Values used in simulations
K joff, K
j
on Dissociation and association constant of IL2 to the j chain of the IL2R K αoff = 0.6 s−1, K αon = 107M−1s−1,
K βoff = 3× 10−3s−1, K βon = 3.4× 106M−1s−1
f j Parameter that control the properties of different IL2m 10−3, 103
N j Switch parameter setting if the mAb blocks (=1) or not (=0) the
interaction of IL2 with the j chain of the IL2R
0, 1
ilaEA , ilaMA Number of cytokine signaling receptors, at the surface of an activated
E and M cells, bounds to an alternative cytokine (not IL2)
108, 107
RaEl , RbEl Total number of alpha and beta chains of IL2R per E cells in the state l RaEN = 10, RaEA = 104, RaEC = 103, RbEl = 103
RaRl , RbRl Total number of alpha and beta chains of IL2R per R cells in the state l RaRN = 104, RaRA =105, RaRC =104, RbRl =103
RaMl , RbMl Total number of alpha and beta chains of IL2R per M cells in the state l RaMl =10, RbMl =104
K αβon , K
αβ
off Association and dissociation rates for the interaction of free beta chain
to preformed IL2/alpha chain complexes, at the T cell membrane
K αβon =2.2 × 10−3s−1, K αβoff= 3× 10−3s−1
K βαon , K
βα
off Association and dissociation rates for the interaction of free alpha chain
to preformed IL2/beta chain complexes, at the T cell membrane
K βαon = 0.6× 10−2s−1, K βαoff = 0.6 s−1
K in Internalization (degradation) rate of signaling IL2/IL2R complex by T cells K in=0.04 min−1
to a system initialized in the tolerant steady state it reinforces the
preexistent tolerance, by further expanding the regulatory popu-
lations (Figure 5). Interestingly, increasing the IL2 dose applied to
a preexistent tolerant state could induce immunity by expanding
the M cells; although, this effect is obtained for significantly high
(unrealistic) values of the IL2 dose.
Thus overall in the model, IL2 injections appear to reinforce
the preexistent steady state, this is expanding transiently either the
R or the E cells respectively for a preexistent tolerant or autoim-
mune situation. A closer look to the model behavior qualitatively
explains these results. Briefly: in a preexistent autoimmune steady
state there is an excess of IL2 in the lymph node, thus is not lack of
IL2 what limits regulatory T cell expansion, is their competition
with auto-reactive E cells for the cognate APCs. In consequence
injecting IL2 would never reestablish tolerance. In a preexistent tol-
erant steady state, there is a small amount of IL2 in the lymph node,
which is almost exclusively used by the regulatory T cells, limit-
ing their expansion. The helper T cells do not expand as result of
the direct suppression of their activation exerted by the R cells. In
this situation the injection of IL2, naturally leads to the enhanced
expansion of R cells reinforcing the suppression over the E cells.
Only when the IL2 concentration is extremely high at the lymph
nodes it triggers a significant expansion of the Memory T cells, sig-
naling through the intermediate affinity IL2 receptor beta-gamma.
The excessive expansion of the M cells in the system affects the sup-
pressive interaction between E and R cells at the APCs, since these
cells, although much weakly, also interact with and compete for
the available APCs.
Interestingly the latter model predictions are indeed compati-
ble with existent experimental observations and further provide a
guideline for its future practical application. On the one hand,
the reinforcement of ongoing immune reactions by IL2 injec-
tions, predicted by the model, explains classical observations on
in vivo animal models, where IL2 have been shown to potentiate
immune reactions to viral infection (35) and to well-adjuvated
vaccines (1–3). In these systems the immune response induced to
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FIGURE 4 | Illustration of the steady states obtained from numerical
simulations of the model. (A,B) shows the proportion of the total T cell
number corresponding to helper (E), regulatory (R), and memory (M) T cells.
The situation showed in (A), corresponds to the autoimmune steady state (IS)
where the memory and helper T cells dominate the system. The situation
depicted in (B), correspond to the tolerant steady state (TS) where the
regulatory T cells dominate the dynamics. The graph in (C) illustrates how
these two types of steady state of the system co-exist in the same region of
parameter values (the region of bistability). It is shown how different initial
conditions, changing just the proportion of E, R, and M cells at time t =0,
leads to trajectories taking the system either in the tolerant (TS) or the
autoimmune (IS) steady state.
FIGURE 5 | Effect of injections of IL2, on the proportion of
helper+memoryT cells versus regulatoryT cells [ratio (E+M)/R], in a
system initialized either in tolerant (TS) or the autoimmune (IS) steady
state. The graph shows the ratio (E+M)/R attained in the system right after
5 days of continuous injections of the indicated dose (x axis of the graph) of
an IL2 with either 10 min (thin curves) or 7 h (thick curves) life span in
solution. It can be seen how when the simulations start with a system at
the TS, the ratio (E+M)/R reduce its values for intermediate dose of the
treatment. This is a direct consequence of a preferential expansion of the R
cells in the system. However, if the dose is further increased then the ratio
(E+M)/R is significantly increased. This is a direct consequence of the
expansion of helper and memory T cells, by the treatment application.
When the treatment start on a system at the IS, then increasing the dose
always leads to an increase of the ratio (E+M)/R. This is, it further
increments the number of E and R cells in the system. Interestingly
increasing the life span of the injected IL2 moves to lower values the dose
ranges where treatment is effective, but does not change the qualitative
pattern of response observed.
the involved foreign antigens, which are most probably loosely or
just not controlled by regulatory T cell activity, is further promoted
by the injected IL2. Furthermore, the observed enhancement of
immunity, in these experimental systems, might not relay just
on the model predicted expansion of helper CD4+ T cells. It
might also involve important direct effects of IL2 on memory
CD8+ T cell and/or NK cells, which are known to be relevant
in many of these particular systems. In any case the model here,
will further predict that optimal application of IL2 for the pur-
pose of enhancing immunity, will be obtained when providing IL2
after the immune reaction have already started and never before,
because some reminiscent of immune regulation might still exist
and could be potentiated by the added IL2.
On the other hand, the capacity of IL2 addition to reinforce
natural tolerance mediated by regulatory T cells, predicted by the
model, explains as well several experimental observations. Par-
ticularly, it explains clinical data stating that regulatory T cells
populations are significantly expanded, both in cancer (9, 36) and
HIV (37) patients, treated with IL2. Such effect might be related
to the poor efficacy observed in these clinical applications of IL2.
Particularly, in the case of cancer, less than 20% of the treated
patients show some anti-tumor effect, perhaps, according to the
model here, because just an small fraction of the patients, happen
to have a naturally preexistent immune response against tumor
antigens, which could be further enhanced by the injected IL2. In
the case HIV patients, IL2 based therapy have led to the recovery
of CD4+ T cells counts, but the patients do not seem to recover
their capacity to fight general infections, perhaps, according to the
model here, because this treatment is just reinforcing tolerance
mediated by regulatory T cell activity.
Furthermore, this second model prediction also explains many
results in pre-clinical animal models. It explains, for instance, that
IL2 injections can prevents allograft rejection (10); or attenuate the
induction of Experimental Autoimmune Encephalomyelitis (EAE)
(10); or fully prevent the development of diabetes in the NOD
mice (11). Interestingly, in the EAE and allograft reaction mod-
els the latter effects are observed for scheme of IL2 applications
where this cytokine is injected in the system before implanting
the allogeneic tissue or before inducing the EAE. This is before
the immune/autoimmune reaction has been expanded; i.e., when
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there is a preexistent natural tolerance, mediated by regulatory T
cells, which could be reinforced by the applied treatment. How-
ever, in the NOD mice model, recent data (12) have shown that
IL2 treatment at the onset of diabetes could revert disease devel-
opment. Interestingly, in this “therapeutically relevant scenario”
treatment efficacy is much lower than in the preventive settings.
Only 40–60% of the NOD mice appear to be cured, while 100%
of the NOD mice are diabetes free when treating in the preventive
settings. Whether or not at the onset of NOD mice diabetes the bal-
ance between regulatory T cells and helpers T cells have been fully
disrupted in favor of immunity, just as considered in our model
simulations of an autoimmune disease therapeutic scenario, is a
matter of discussion. Actually Grinberg-Bleyer et al. have shown
that at the onset of NOD diabetes a significant amount of regu-
latory T cells can still be found in the pancreas and its draining
lymph node. Unfortunately in the NOD mice, the acute nature
of diabetes development (with a full irreversible destruction beta
islet) invalidates any displacement of the treatment application
toward a more advanced stage of the disease, to better compare
with our model predictions.
Simulating the injections of different anti-IL2 mAbs
Anti-IL2 antibodies are molecules that form complexes with the
IL2, blocking or not its binding to the different chains of the IL2
receptor at the T cell surface and therefore interfering with the
associated signaling process. Three classes of antibodies are sys-
tematically explored in our simulations following its documented
existence in the literature (20, 38): (1) The anti-IL2 mAbs, which
bind and thus block the site in the IL2 surface implicated on the
interaction with the alpha chain of the IL2 receptor (referred here
as the face alpha mAbs); (2) The anti-IL2 mAbs, which bind and
thus block the site in the IL2 surface implicated on the interaction
with the beta chain of the IL2 receptor (referred here as face beta
mAbs); and (3) the anti-IL2, which block the binding of IL2 to all
chains of the IL2 receptor (referred here as a fully blocking mAbs).
The injection of monoclonal antibodies anti-IL2, in the model
simulations, when applied to a previously tolerant system could
induce a breakdown of tolerance (Figure 6A), with the consequent
transition of the system to the autoimmune steady state. Such
effect can be obtained with the three classes of anti-IL2 mAbs stud-
ied, but it requires a minimal effective dose of the anti-IL2 mAb
and treatment duration (Figure 6A) which varies significantly with
the type of mAbs used. Face alpha mAbs are significantly more
efficient than fully blocking or face beta mAbs (Figure 6A) in this
simulation. Moreover, for the three classes of mAbs studied the
higher the affinity for the IL2 the higher their efficacy in these
simulation (27).
The effect of treatment with anti-IL2 mAbs in a system with
a preexistent autoimmune reaction is also quite significant. In
this case, the treatment is capable of resetting the system into the
FIGURE 6 | Effect of the simulation of treatments of IL2 depletion, using
different anti-IL2 antibodies. mAbs in the simulation, can block the
interaction of IL2 with the alpha (face alpha mAb), or with the beta (face beta
mAb) or with both (fully blocking mAb) chains of the IL2R. The graphs in
(A) corresponds to the case in which the treatment induces a breakdown of
the preexistent tolerant steady state, i.e., a transition to the autoimmune
steady state. The graphs in (B) corresponds to the case in which treatment
induces tolerance, taking into the tolerant steady state, a system initially set
in the autoimmune steady state. Breakdown of a preexistent tolerant state
requires a minimal effective dose of mAb and treatment duration [graph in the
right side of (A)]. In this scenario, face alpha mAbs are more efficient than
face beta or fully blocking mAb. This means that the latter need higher doses
of mAb to achieve a similar effect. Induction of tolerance requires minimum
treatment duration with a mAb dose inside an intermediate window of values
[graph in the right side of (B)]. This effect is obtained when face alpha, face
beta, or fully blocking mAbs are used.
Frontiers in Immunology | T Cell Biology December 2013 | Volume 4 | Article 439 | 10
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
León et al. Modeling the role of IL2 in T cell dynamics
tolerant steady state (i.e., inducing tolerance) (Figure 6B). This
effect occur under quite restrictive treatment conditions: there is
a minimal treatment duration required and the dose of the anti-
IL2 mAbs used has to be set inside some particular intermediate
range of values (Figure 6B). The tolerogenic effect of the anti-IL2
mAbs is obtained with all type of mAbs (Figure 6B). Differences in
the mAbs affinity and mAbs class strongly change the dose range
where this effect is observed2.
Overall the simulations of IL2 depletion treatments using anti-
IL2 antibodies predict that this type of therapy is able to break a
preexistent tolerant state, inducing an autoimmune response, or
to render tolerant a preexistent autoimmune system. A closer look
to the model behavior qualitatively explains these results as fol-
lows. The injected mAbs appear to sequester the IL2, limiting its
availability to provide signal to the T cells. When the treatment is
applied into an initially tolerant steady state, the initial effective
concentration of IL2 is low and it is further reduced to insignifi-
cant levels, where this cytokine is incapable to signal neither to E,
R, or M cells. Therefore, if the treatment is sustained long enough,
the number of R cells fall down to a minimum determined by the
size of the thymic output, because the proliferation and survival
of R cells is strictly dependent on IL2. But the number of E cells,
on the other hand, set back to a value determined by the avail-
ability of the homeostatic cytokine of ILα, which they could use
as alternative to IL2 signal. Therefore once the injected mAbs are
cleared, the auto-reactive E cells could have some initial advantage
in respect to the R cells, leading the T cell expansion, which drive
the system into the autoimmune steady state. However, when the
treatment is applied to an initially autoimmune system, the effec-
tive concentration of IL2 is quite large and it is reduced by the
presence of the antibody. The efficacy of the mAbs to affect IL2
signaling in the different T cell population is strongly dependent
on its affinity for the IL2 and the side of the IL2 recognized. For
a very high antibody dose, the effective IL2 concentration falls to
negligible values, which as before are unable to signal neither to E,
R, or M cells. Thus the size of the auto-reactive E cell population is
reduced to the value set by the availability of ILα and the number
of R cell remains low in a value determined by the size of thymic
output. When the injected antibody is cleared the system could
return back to the autoimmune equilibrium. However, for some
intermediate doses of the antibody, the effective IL2 concentration
is reduced to values where it is unable to signal on the E and M cells,
but it is still significant for the R cells, which are more sensitive due
to their higher expression of the alpha chain of the IL2 receptor.
Therefore, for these mAbs doses the E cell population is reduced
to the minimal size, which can be sustained by the available ILα.
But the R cells are stimulated to grow forcing the system to switch
into the tolerant steady state.
2Treatment using the face alpha mAbs is the best option (it work for lower MAb dose
windows, example shown in Figure 6B) when the mAb used has an affinity for IL2
lower than 1010 M−1. But the capacity of this mAb to revert an autoimmune state
is completely lost if the mAb affinity for IL2 is assumed to be higher. The face beta
mAbs seems to work well for a larger range of mAbs affinities. Its effect is lost only
for unrealistically high affinities (larger than 1011 M−1) and it is always better than
the one obtained with a fully blocking mAb. In Ref. (27), Figure 7, we presented
results considering a mAb affinity higher than 1010 M−1, where the face alpha mAb
is not effective in reverting an autoimmune state.
The model prediction of a higher efficacy of treatments with
face alpha mAbs, to break a preexistent tolerant steady state, relates
to the impact of this type of mAbs on the dynamics of the M
cells. Face alpha mAbs bind the available IL2 forming immune-
complexes that can still signal through the intermediate affinity
IL2 receptor (beta+ gamma chain). This form of the receptor is
prevalent in the M cells, thus face alpha mAbs partially redirect IL2
signaling into the M cells expanding this population. The growth
of the M cells interferes with the dynamics of CD4+ T cells, i.e., M
cells consume the available IL2 and reduce the capacity of CD4+
T cells to interact with the APCs. The combination of the latter
effects explains the advantage of the face alpha mAb to break a pre-
existent tolerant steady state. On the other hand, the differences
observed between fully blocking and face beta mAbs in the model
simulations (compare dose dependencies in Figure 6), must rely
on the fact that face beta mAbs do not block the interaction with
the alpha chain of the IL2 receptor, conditioning the attachment
of the immune-complexes formed to cells that express this mole-
cule at the cells surface. These interactions significantly alter the
bio-distribution of both the IL2 and the antibody.
Interestingly, the latter model predictions are indeed compat-
ible with existent experimental observations. On the one hand,
the predicted capacity of treatments blocking IL2 activity to
promote autoimmunity/immunity, explains observations where
monoclonal antibodies against IL2 have been shown to promote
effective immune responses to tumors (16) and to induce autoim-
mune disease in naïve mice (13). In both cases, the model explains
the observed effects as being associated to the treatment capacity
to weaken regulatory cell activity, just as argued by their origi-
nal authors. It must be also noted that in these reports the S4B6
anti-IL2 mAbs was used, a mAb which has been recently proven
to block only the interaction of IL2 with the alpha chain of the IL2
receptor (38).
On the other hand, the model predicted capacity of IL2 block-
ing therapies to reestablish tolerance in the context of ongoing
immune/autoimmune reactions, is not documented in the litera-
ture. This model prediction is very interesting from the practical
perspectives for the treatment of autoimmune diseases. How-
ever, the fact that the predicted treatment effect just occurs for
a particular intermediate range of antibody doses, applied dur-
ing a relatively long period of time, makes difficult the practical
implementation of the treatment. To overcome the latter problem
we suggested, based on model simulations, an alternative/simpler
strategy to capitalize this therapeutic effect. A large initial dose
of the mAb could be used, reducing it periodically with a fixed
rate. With this alternative strategy the model predict a much sim-
pler dose dependency (see Figure 7) of treatment efficacy, i.e., the
applied initial dose used must be large enough (as to induce sig-
nificant initial immunosuppression), and the reduction rate used
should be sufficiently slow.
Simulating the injection of IL2/mAb immune-complexes
Immune-complexes of IL2 plus anti-IL2 mAbs (in a 1:2 mAb:IL2
molar proportion), has been recently highlighted as a novel ther-
apeutic strategy (18, 20, 39) which could significantly potentiate
the activity of the IL2 in vivo. Intuitively it should be expected
that the therapy with immune-complexes share properties with
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FIGURE 7 |The graph summarizes the results of simulations of a
model system set initially to the IS and then perturbed with, an initial
dose of the face beta mAb, which is periodically reduced to the half at
the indicated time (x axis). The curve indicates the minimal value of the
initial mAb dose required to induce tolerance (taking the system into the
tolerant steady state) with the applied treatment.
the therapies based on its basic components, but their comparative
efficacy shall depend on the class and the affinity of the mAbs used.
In our simulations, immune-complexes can either reinforce or
weaken a preexistent tolerant steady state depending on the class
of mAb used on its formulation. Figure 5, shows how the injec-
tion of immune-complexes significantly changes the number of
E, R, and M cells in the system initially set to the tolerant steady
state. Immune-complexes formed with beta face or fully blocking
mAbs induce a quite significant transient expansion of Regulatory
T cells (reinforcing the tolerant state). This transient expansion of
the Regulatory T cells is significantly larger than the one induced
by an equivalent treatment with IL2 alone and it is maximal for
mAbs with some intermediate affinity for the IL2 (27). However,
immune-complexes formed with face alpha mAbs have a quite
different effect in these simulations (Figure 8). They could also
expand the R cells, but they expand much more in comparison
the M cells in the lymph node. The capacity of this immune com-
plex to expand M cells became larger as their affinity for the IL2
is increased (27). Interestingly for the three classes of immune-
complexes a sufficiently high dose of the latter treatment could
induce a breakdown of tolerance. But only immune-complexes
based on face alpha mAbs perform better in this task than the
therapy based on the anti-IL2 mAb or the IL2 alone (Figure 9).
When applied to initially autoimmune steady states, all
immune-complexes fail to reestablish tolerance steady state. As
the injection of IL2 the immune-complexes further reinforce a
preexistent autoimmune steady state, expanding the helper and
memory T cells (Figure 8).
Summarizing the results above shows that immune complex
can sometimes synergistically potentiate the effects of IL2 and
mAbs. Complexes based on face alpha mAbs do promote immu-
nity primarily by expanding the M cells, and leading ultimately
to a quite efficient breakdown of a preexistent tolerant steady
state. Complexes based on face beta mAbs, can efficiently rein-
force tolerance expanding significantly the R cells preexistent in
FIGURE 8 | Effect of injections for five days of the indicated doses of
immune-complexes of IL2 plus antibodies anti-IL2, on the ratio of
helper+memoryT cells versus regulatoryT cells [ratio (E+M)/R], in a
system initialized either in tolerant (TS) or the autoimmune (IS) steady
state. Different immune-complexes differ on the class of mAb used to form
it (face alpha, face beta or fully blocking mAbs). immune-complexes are
always formed with a 1:2 molar ratio of mAbs:IL2 and the dose applied is
reported in terms of the mass of IL2 injected. If the simulations start with a
system at the TS, immune-complexes formed with face beta or fully
blocking mAbs reduce the ratio (E+M)/R for some intermediate dose
values and then increases it for higher dose values. This is a pattern of
response, qualitatively similar to that obtained with IL2 injection, but
significantly displaced to the range of lower doses of IL2. If face alpha
mAbs are used to form the complex the pattern of response obtained is
qualitatively different. The ratio (E+M)/R always increase (favoring the
expansion of E and M cells) and the larger the dose applied the larger the
increment. If the simulations start with a system at the IS, all the possible
immune-complexes behave qualitatively like the IL2 alone, they promote in
dose-dependent way a further expansion of E and R cells, increasing the
ratio (E+M)/R.
the tolerant steady state. Face alpha mAbs for immune-complexes
are better with the highest possible affinity, but face beta mAbs
could be better with some intermediate affinity values.
Qualitatively the effects of immune-complexes can be explained
based on two main dynamical properties in the model: (A) In the
immune complex the IL2 is protected from degradation. While
bind to the mAbs the IL2 has a life span of 3 days (like the mAbs),
which is significantly larger than the life span of 10 min reported
for free IL2. (B) Immune-complexes block different sites in the sur-
face of IL2 conditioning its preferential interaction with different
cell populations, accordingly to their differential expression of the
IL2 receptor chains. Face alpha mAbs, form immune-complexes
that bind and signal through the beta+ gamma pair of IL2 recep-
tors. Thus, since beta chain is over-expressed by the M cells, this
complex preferentially redirect the IL2 signal to these cells. Follow-
ing this analysis one could easily explain why this type of immune
complex has a maximal efficiency when the affinity of the face
alpha mAbs used is high. With high affinity mAbs, the IL2 is
more protected from degradation, and the signaling is maximally
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FIGURE 9 |The graph shows the minimal effective dose of mAb (left y
axis) or IL2 (right y axis) versus treatment duration, required to induce
the transition to the IS in a system initialized in theTS, for the
treatment with immune-complexes formed with face alpha mAbs in
the optimal molar proportion 1:2 (mAb:IL2). For direct comparison the
equivalent curves obtained for treatments with the same mAbs alone or
the IL2 alone are also depicted. It can be seen that the injection of this
class of immune complex is more efficient than the injection of the mAb or
the IL2 alone to breakdown tolerance in an initial tolerant system, i.e., it
requires less dose of either the mAbs or IL2 as compared to the
independent treatments.
redirected to the M cells. Face beta mAbs form immune-complexes
unable to signal in any class of IL2 receptor. Thus to mediate any
biological activity this type of complex has to partially dissociate,
working as a controlled source of free IL2. If the affinity of the face
beta mAbs in the complex is too high then the IL2 is never released
and the immune-complexes have no effect at all. If the affinity of
the face beta mAbs is too low, then injecting the complex is like
injecting IL2 alone. However, if the affinity of the face beta mAbs in
the complex is larger than the affinity of the dimeric IL2 receptor
(beta+ gamma chain), but lower than the affinity of the trimeric
IL2 receptor (alpha+ beta+ gamma chain), the IL2 in the com-
plex is easily release to provide signal through the high affinity
trimeric IL2 receptor, but not through the intermediate affinity
dimeric IL2 receptor. In this way the face beta based immune-
complexes provided a preferential signaling to the regulatory cells,
which overexpress the alpha chain of the IL2 receptor.
Interestingly the model results explain available pre-clinical
data on the use of immune-complexes of IL2-anti-IL2 mAbs. Our
observations that immune-complexes formed with face alpha or
face beta mAbs expand different cell populations when injected
in vivo into a normal (tolerant) mouse are fully compatible with
the results reported in Ref. (18, 20, 39). In these experiments,
the S4B6 mAb (a face alpha mAbs) is shown to form immune-
complexes that strongly expands CD8+CD44+ T cells and to a
lesser extent the R cells (20). This face alpha immune complex has
been also used to increment the immune response induced with
a vaccine (17), showing a significantly higher efficiency than IL2
alone. Moreover, the group of Jonathan Sprent have shown that
JES6-1 (originally described as a face beta mAbs (20), although
it has been recently observed that it also blocks the interaction
with CD25, behaving more like a fully blocking mAbs) induce
a larger expansion of Tregs (CD4+CD25+Foxp3+ T cells) than
the injection of IL2 alone in the same experimental setting (20).
Remarkably, this latter type of immune complex has been shown
to reinforce a preexistent tolerance state, preventing graft rejection
or autoimmune disease induction in mice (18). But it showed no
effect when applied in a therapeutic setting, this is just after the
onset of the autoimmune disease or the initiation of skin graft
rejection process (18).
The simulations, however, propose some interesting guidelines
to improve the therapeutic effect of immune-complexes. They pre-
dict that in the case of complexes using face alpha mAbs, the best
strategy is to use mAbs with the higher affinity available. But in
the case of immune-complexes formed with face Beta or fully
blocking mAbs, the use of intermediate affinity mAbs is recom-
mended. Other important prediction of our model simulations is
that treatment with immune-complexes based on face beta or fully
blocking mAbs are useful to reinforce a preexistent tolerant state
preventing the induction of autoimmunity, but it would be quite
inefficient to therapeutically treat an already established autoim-
mune disorder. For the later task, the best strategy would be to
use the anti-IL2 mAbs alone following the strategies described in
Section “Simulating the Injections of Different Anti-IL2 mAbs.”
Simulating the injection of IL2 mutants
Several mutant variants of IL2 have been designed aiming to
improve the therapeutic efficacy of wild-type IL2 in cancer ther-
apy. Most strategies, so far explored, involve the development of
IL-2 variants with an either reduced or increased binding affinity
for the alpha or the beta chain of the IL2R. In this section three
particular classes of mutants are simulated: (a) IL2 Mutant with
a reduced conjugation affinity for the alpha chain of the IL-2R as
the one described in Ref. (40) (referred here as No-alpha mutants);
(b) IL2 Mutant with an increased conjugation affinity for the alpha
chain of IL-2R as the one described in Ref. (41) (referred here as
Alpha-Plus mutants); (c) IL2 Mutant with an increased affinity
for the beta chain of the IL2R as the one described in Ref. (42)
(referred here as Beta-Plus mutant). These three classes of IL2
mutants provide a functional IL2 signal to T cells, since they keep
binding beta and gamma unit of the IL2 receptor (i.e., they are
IL2 agonists). But they might be expected to alter the natural bal-
ance in which wild-type IL2 is consumed by different T cell types,
resulting on a significantly different overall dynamics.
Figure 10A show the effect of injecting different IL2 variants
in a system initially set in the tolerant steady state. As described in
Section “Simulating the Injection of IL2,” injection of wild-type
IL2 transiently reinforce this preexistent tolerant steady state, pref-
erentially expanding the Regulatory T cells in the system. Alpha-
Plus IL2 mutants, exhibit a similar response pattern than wtIL2,
but with an even more marked preferential expansion of the regu-
latory T cells. In contrast, No-Alpha and Beta-Plus mutants show
a completely different response pattern than wild-type IL2. This
class of mutants expand preferentially the helper T cells (E+M),
rather than the regulatory T cells at all injection doses. Moreover
injections of the three classes of mutants, as for the wild-type IL2,
could lead to a breakdown of tolerance in the system when the
dose used is significantly increased. However, the minimal dose
required for such effect is significantly lower for the No-Alpha
mutants and Beta-Plus mutant Figure 10B, than for wild-type IL2
and Alpha-Plus mutants.
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FIGURE 10 |The graph in (A) shows the effect of injections for 5 days at
the indicated dose of different mutant variants of IL2 on the ratio of
helper+memoryT cells versus regulatoryT cells [ratio (E+M)/R], in a
system initialized either in the tolerant (TS) or the autoimmune (IS)
steady state. Mutants differ on their capacity to bind to the different chains of
the IL2R. Alpha-plus and Beta-plus mutants have higher binding affinity than
wild-type IL2 respectively for the alpha chain (f α =1000, f β =1) and the beta
chain (f α =1, f β =1000), while No-alpha mutant lack the binding to the alpha
chain (f α =0.001, f β =1). All mutant variants were simulated with a life span
of 7 h. If the simulations start with a system at the TS, Alpha-plus mutant
reduces the ratio (E+M)/R for some intermediate dose values and then
increases it for higher dose values. This is a pattern of response, qualitatively
similar to that obtained with IL2 injection, although with a slighter wider range
of treatment dose with ratio (E+M)/R reduced from its starting value. If
No-alpha or Beta-plus mutants are used the pattern of response obtained is
qualitatively different. The ratio (E+M)/R always increase (favoring the
expansion of E and M cells) and the larger the dose applied the larger the
increment. If the simulations start with a system at the IS, all the mutants
variants behave like the wild-type IL2, they promote in dose-dependent way a
further expansion of E and R cells, increasing the ratio (E+M)/R. The graph in
(B) shows the minimal effective dose versus the treatment duration, required
to induce the transition to the IS in a system initialized in the TS, for the
treatment with different variants of IL2 mutants. It can be seen that the
injection of No-alpha and Beta-Plus IL2 mutants is more efficient than the
injection of wild-type IL2 alone to breakdown tolerance in an initial tolerant
system, i.e., it requires less dose to achieve a similar effect.
Figure 10A also shows the effect of injecting different classes
of IL2 mutants in a model system initially set in the autoimmune
steady state. In this case the three classes of mutants behave quite
similarly to wild-type IL2, i.e., None of them is able to promote
a transition to a tolerant steady states, at any dose and treat-
ment duration. Moreover, they reinforce the preexistent autoim-
mune steady state, further expanding the Helper and Memory
T cells.
Overall the result in this section show that No-Alpha and
Beta-Plus IL2 mutants behave quite similarly, being significantly
better than wild-type IL2 to promote immunity. While Alpha-Plus
mutants could be slightly better that wild-type IL2 to reinforce a
preexistent tolerant state, expanding more the regulatory T cells.
Qualitatively, the latter results could be easily understood in the
model, by taking into account the differential expression of the
high affinity/trimeric form (alpha+ beta+ gamma) and interme-
diate affinities/dimeric form (beta+ gamma) of the IL2 receptors
on the different T cell populations. Regulatory T cells, relay on
the overexpression of the alpha chain of the IL2R, to have the
highest expression of the high affinity form of the IL2R. Memory
T cells relay in the overexpression of the beta chain of the IL2
R to have the higest expression level of the intermediate affinity
form of the IL2R. The No-Alpha and Beta-Plus mutants have a
similar impact in the balance of use of IL2 related signal in the
model. In both cases the resulting mutants lack the preferential
capacity to signal over Regulatory T cells at low concentration,
which is characteristic of the wild-type IL2. Furthermore they will
preferentially redirect the signal toward the memory T cells, and
strongly promote immunity. As the reverse case the Alpha-Plus
mutant, reinforce the capacity of the wild-type IL2 to signal pref-
erentially over the Regulatory T cells, resulting on a better tool to
reinforce a preexistent tolerance state.
The results obtained above are compatible with existent experi-
mental data. Both No-alpha (40) and Beta-Plus (42) mutants have
been shown to induce a more potent anti-tumoral response than
wild-type IL2 in several transplantable tumor models in mice. The
dynamic effects predicted in silico for these types of IL-2 mutants is
qualitatively similar to those described in Sections “Simulating the
Injection of IL2/mAb Immune-Complexes” for treatments with
immune-complexes of IL-2 and anti-IL-2 mAbs, when face alpha
mAb are used. Indeed No-Alpha mutants can be easily conceptu-
alized as an extreme case of such immune-complexes if the affinity
of the mAbs for the IL2 tends to infinity. From a quantitative point
of view, in the model, IL2 mutants can become as efficient as the
immune-complexes, only when its life span is set to be greater than
24 h. If the life span of the mutant is taken to be of 7 h (the one used
in Figure 10), which is the one reported for a wtIL2 fused to a con-
stant region of IgG (43), then one might need around 5–10 time
more mutant than wtIL2 in the immune-complex to obtain an
equivalent effect. However, since immune-complexes work in vivo
at very low concentrations of IL2, 1–2 micrograms in mice (20),
a quite reasonably small amount of the IL2 mutants would be
required to induce a similar effect. Thus, these IL2 mutants can be
useful tools to promote immunity, for instance to treat tumors or
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to enhance the response to cancer vaccines. It is important to note
that mutants might have some regulatory/developmental advan-
tages as potential drugs in comparison to the immune-complexes,
given the fact that they are single molecules.
The predicted capacity of Alpha-Plus mutants to reinforce pre-
existent tolerant steady state, expanding the regulatory T cells, has
never been evaluated. A mutant variant of IL2 with 1000 times’
higher affinity for the IL-2Ra was developed by Rao et al. (41).
But only the in vitro effect of this mutant on different T cell lines
was evaluated. Potentially the Alpha-Plus mutant could be used
to treat patients that would receive an organ transplant to reduce
the risk of graft rejection. However from a quantitative point of
view the mutant efficacy expanding regulatory T cells is predicted
only as slightly better than that of wild-type IL2. Moreover, it is
quite similar to that obtained with immune-complexes of IL2-
anti-IL2 mAbs formed with face beta or fully blocking mAbs (see
Simulating the injection of IL2/mAb immune-complexes), when
its life span is set to be of around 7 h (the value used in Figure 10).
This is when its life span is similar to that reported for a wtIL2
fused to a constant region of IgG (43). Therefore this Alpha-plus
mutant or just simply the wild-type IL2 fused to Fc of IgG, could
be a reasonable drug to prevent allograft rejection. They might
have a similar effect to that reported for immune-complexes in
mice, but being much simpler drugs to develop. Indeed a ver-
sion of IL2 fused to Fc portions of immunoglobulin is already
available (43).
CONCLUDING REMARKS
Mathematical modeling of the IL2 and T-cell dynamics, consid-
ering the dual role of IL2 in its interaction with regulatory and
helper CD4+ T cells, is able to explain the complexity observed in
the effects of IL2 modulating treatments. In this sense, we show
that the model explains a large amount of available clinical and
pre-clinical data. Moreover, it predicts optimal strategies for the
future application of these treatments:
(A) Mutant variants of IL2, either with reduced affinity for CD25
(the alpha chain of IL2 receptor) or an increased affinity for
CD122 (the beta chain of IL2 receptor), and with an increased
life span in circulation (for instance fusing them to Fc portion
of IgG), are the best strategy to potentiate immunity alone or
in combination with vaccines.
(B) Increasing IL2 life span in circulation, either by fusing it with
larger proteins or forming complexes with mAbs that block
the interaction of IL2 and CD122 (the beta chain of the IL2
receptor), significantly potentiate its capacity to reinforce a
preexistent natural tolerance, further expanding the regula-
tory T cells. This effect might be useful to treat patients that
would receive an organ transplant, reducing the risk of graft
rejection.
(C) Anti-IL2 antibodies which block the interaction of IL2 with
CD122, CD25, or both can be used to treat an ongoing
autoimmune disorder, promoting the induction of tolerance.
The best schedule for this therapy is to start treatment with a
high dose of the mAb (one capable to induce some immune
suppression) and then scale the dose down slowly the dose in
subsequent applications.
Last, but not least, it is important to highlight that our
model has focused on the control that IL2 exerts on T cell cycle
progression, impacting both in T cell proliferation and survival.
We have neglected some other reported roles of IL2 in T cell dif-
ferentiation. For instance, IL2 has been reported to increase the
suppressive capacity of the Regulatory T cells (12); to condition
the differentiation of CD8 T cells into a memory phenotype (44,
45); to induce together with TGFb, the generation of the so called
induced Tregs from naïve CD4+ T cells (46). We believe these
phenomena, although important in some experimental contexts,
are not essential to understands the main phenomenology stud-
ies in this paper. In future studies, the current model could be
extended to include some or all of the above referred interactions
of IL2.
Moreover, severe toxicity, i.e., the appearance of the cytokine
storm and the vascular leak syndrome, is perhaps the major limi-
tation known today of the practical application of IL2 modulation
treatments in clinics. Our model cannot be used to simulate
directly the toxic effects of the different IL2 modulation treatments
studied. It could only be used to predict strategies that optimize
the expected therapeutic efficacy related to the balance between
regulatory and effector CD4+ T cells. However, a recent report by
the group of Boyman (47) has shown that vascular leak syndrome,
which leads to severe pulmonary edema, is caused by the direct
interaction of IL2 with its high affinity receptor expressed in lung
epithelial cells. They demonstrated that treatment with immune-
complexes of IL2+ S4B6 mAbs (anti-IL2 mAb which interferes the
binding of IL2 to the alpha chain of IL2 receptor), prevents vascu-
lar leak syndrome while inducing a potent anti-tumor response.
Furthermore, in Carmenate el al. (40), treatment with IL2 mutants
with a reduced affinity for CD25 (no-alpha mutant) was shown
to be less toxic than treatment with wild-type IL2. These exper-
imental observations support the practical feasibility of some of
our model predictions.
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APPENDIX A
DYNAMICS IN THE BLOOD COMPARTMENT
Equations for the dynamics in the blood compartment are the
following:
dIL2S
dt
= K Aboff × IL2AbS − K Abon ×
1
NA × VS × IL2S
× AbS + NLN ×
(
Dil
IL2
fve× VLN − Dil
IL2S
VS
)
− Kdi × IL2S + Γi (A1)
dIL2mS
dt
= NLN ×
(
Dil
IL2m
fve× VLN − Dil
IL2mS
VS
)
− Kdi × IL2mS + Γmi (A2)
dAbS
dt
= K Aboff × IL2AbS − K Abon ×
1
NA × VS × IL2S
× AbS + NLN ×
(
Dab
Ab
fve× VLN − Dab
AbS
VS
)
− Kda × AbS + Γab (A3)
dIL2AbS
dt
= −K Aboff × IL2AbS + K Abon ×
1
NA × VS × IL2S
× AbS + NLN ×
(
Dab
IL2Ab
fve× VLN − Dab
IL2AbS
VS
)
− Kda × IL2AbS (A4)
Equations A1–A3 model the dynamics of IL2 (IL2s), IL2 mutant
variants (IL2ms), and anti-IL2 antibodies (Abs) number respec-
tively, while the dynamics of the number of immune-complexes
IL2+ anti-IL2 antibodies (IL2Abs ) is modeled by Eq. A4. The vari-
ables and parameters involved in these equations are defined in
Table 1.
Equations A1, A3, and A4 consider the increase in the num-
ber of IL2 and mAbs in the blood due to the dissociation process
of immune-complexes with a constant rate (K Aboff ), which corre-
sponds to a decrease in the amount of these complexes (first term
in Eqs A1, A3, and A4). The process of formation of immune-
complexes, through the association of IL2 and mAb with a constant
rate (K Abon ), is taken into account in the second term in Eqs A1, A3,
and A4. The exchange of molecules between blood and peripheral
lymph nodes is modeled as a simple diffusion process that bal-
ances the molecule concentrations in both compartments (third
term in Eqs A1, A3, and A4; first term in Eq. A2). The number
of molecules decays exponentially with a constant rate (K di, K da),
due to renal elimination in kidney (fourth term in Eqs A1, A3, and
A4 and second term in Eq. A2). Finally, an external source for IL2,
IL2m, and mAbs is considered, which causes an increase in the
number of these molecules in the compartment (last term in Eqs
A1–A3).
APPENDIX B
DYNAMICS OF T CELLS IN THE LYMPH NODE COMPARTMENT
The dynamics of the number of T cells in the lymph node com-
partment, following the process described above, are modeled with
the following set of equations:
d EN
dt
= Γe − K EA × EBN ×
(
1− R
B
T
s × A
)(s−1)
+ αE × K ES ×
(
1− (SigE)
h
(SE)
h + (SigE)h
)
× EA
+ 2 K EP × EC − K Ed × EFN (B1)
d EA
dt
= K EA × EBN ×
(
1− R
B
T
s × A
)(s−1)
− K ES × EA (B2)
d EC
dt
= K ES ×
(
(SigE)h
(SE)
h + (SigE)h
)
× EA − K EP × EC (B3)
d RN
dt
= Γr − K RA × RBN + αR × K RS
×
(
1− (SigR)
h
(SR)
h + (SigR)h
)
× RA + 2 K RP
× RC − K Rd × RFN (B4)
d RA
dt
= K RA × RBN − K RS × RA (B5)
d RC
dt
= K RS ×
(
(SigR)h
(SR)
h + (SigR)h
)
× RA − K RP × RC (B6)
d MA
dt
= −K MS ×
(
(SigM)h
(SM)
h + (SigM)h
)
×MA + 2
× K MP ×MC − K Md ×MA (B7)
d MC
dt
= K MS ×
(
(SigM)h
(SM)
h + (SigM)h
)
×MA − K MP ×MC (B8)
K E
VLN
= EBl /(EFl × F);
K R
VLN
= RBl /(RFl × F);
K M
VLN
= M Bl /(M Fl × F) (B9)
F = s × A −
∑
l
EBl −
∑
l
RBl −
∑
l
M Bl ;
∀l ∈ {N, A, C} (B10)
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The dynamics of the number of Helper and Regulatory CD4+
T cells, on their three different functional states of their life cycle
[resting (EN, RN), activated (EA, RA) and cycling (EC, RC) cells],
is modeled using Eqs B1–B6, respectively; while the dynamics of
the number of Memory CD8+ T cells on its two functional states
[activated (MA) and cycling (M C) cells] is modeled with Eqs B7
and B8. The process of conjugation of T cells, on their different
functional states, with their cognate APCs is modeled assuming
quasi-steady state equilibrium, which leads to the equations pre-
sented in Eq. B9 [see a more detailed explanation of the derivation
of these equations in (28)]. In Eq. B9, the symbolic label l denotes
the functional state of the cell (l=N : resting, l=A: activated,
l=C : cycling); and the superscript B and F denotes the cells con-
jugated to APC or free, respectively. The definitions of variables
and parameters in Eqs B1–B9 are resumed in Table 2.
Equations B1–B6 considered that resting E and R cells are pro-
duced by the thymus (first term in Eqs B1 and B4), and they die
with a constant rate K Ed and K
R
d , respectively (last term in Eqs
B1 and B4). Resting cells become activated after conjugation with
APCs, process which is inhibited in E cells by the presence of co-
conjugated R cells in the same APC (second term in Eqs B1 and
B4; first term in Eqs B2 and B5). Activated T cells require enough
cytokine derived signals to become cycling cells (first term in Eqs
B3 and B6). The fraction of activated cells obtaining these sig-
nals is computed with a sigmoid function of the mean number of
bound cytokines signaling receptors per cell (SigE, SigR). In the
absence of these signals, a fraction α of the activated cells revert
to the resting state (third term in Eqs B1 and B4) and the remain-
ing fraction (1− α) simply die. The cycling E and R cells divide
producing two new resting cells with a constant rate K Ep and K
R
p ,
respectively (fourth term in Eqs B1 and B4; second term in Eqs B3
and B6).
The Eqs B7 and B8 describe the dynamics of memory CD8+
T cells. In these equations, is modeled the dynamics of M cells
analogous that for E cells. The only difference is that M cells are
considered pre-activated cells, which become cycling in response
to cytokine signals (first term in Eqs B7 and B8). The cycling M
cells divide producing two new activated cells with a constant rate
K Mp (second term in Eqs B7 and B8). The activated cells die with a
constant rate K Md (last term in Eq. B7).
APPENDIX C
DYNAMICS OF MOLECULES IN THE LYMPH NODE
The equations in the model describing the dynamics of the number
of molecules circulating in the Lymph Node (IL2, anti-IL2 anti-
bodies, and immune-complexes) and the number of complexes
IL2-IL2R and IL2-mAb-IL2R formed in a single cell membrane
are the following:
dIL2
dt
= K Aboff × IL2Ab −
1
NA × fve× VLN K
Ab
on × IL2× Ab
−
(
Dil
IL2
fve× VLN − Dil
IL2S
VS
)
+ Kpi × K EA × EBN
×
(
1− R
B
T
s × A
)(s−1)
+
∑
j
K
j
off
×
[∑
l
(CElj ×El)+
∑
l
(CRlj ×Rl)+
∑
l
(CMlj ×Ml)
]
−
∑
j
1
NA × fve× VLN K
j
on × IL2
×
[∑
l
(PElj ×El)+
∑
l
(PRlj ×Rl)+
∑
l
(PMlj ×Ml)
]
(C1)
dIL2m
dt
= −
(
Dil
IL2m
fve× VLN − Dil
IL2mS
VS
)
+
∑
j
K
j
off
×
[∑
l
(CmElj × El )+
∑
l
(CmRlj × Rl )
+
∑
l
(CmMlj ×Ml )
]
−
∑
j
fj × 1
NA × fve× VLN K
j
on × IL2m
×
[∑
l
(PElj ×El )+
∑
l
(PRlj ×Rl )+
∑
l
(PMlj ×Ml )
]
(C2)
dAb
dt
= K Aboff × IL2Ab −
1
NA × fve× VLN K
Ab
on
× IL2× Ab−
(
Dab
Ab
fve× VLN − Dab
AbS
VS
)
+
∑
j
(1− Nj)×
[
K Aboff ×
∑
l
(CAbElj × El
+ CAbRlj × Rl + CAbMlj ×Ml)
]
−
∑
j
(1− Nj)×
[
1
NA × fve× VLN K
Ab
on × Ab
×
∑
l
(
CElj × El + CRlj × Rl + CMlj ×Ml
)]
(C3)
dIL2Ab
dt
= −K Aboff × IL2Ab +
1
NA × fve× VLN K
Ab
on
× IL2× Ab−
(
Dab
IL2Ab
fve× VLN − Dab
IL2AbS
VS
)
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+
∑
j
(1− Nj )× K joff
×
[∑
l
(CAbElj × El )+
∑
l
(CAbRlj × Rl )
+
∑
l
(CAbMlj ×Ml )
]
−
∑
j
(1− Nj )
× 1
NA × fve× VLN K
j
on × IL2Ab
×
[∑
l
(PElj × El )+
∑
l
(PRlj × Rl )
+
∑
l
(PMlj ×Ml )
]
(C4)
dCmElα
dt
= fα × K αon ×
1
NA × fve× VLN
× IL2m× PElα − K αoff × CmElα − fβ × K αβon
× CmElα × PElβ + K αβoff × TmEl (C5)
dCmElβ
dt
= fβ × K βon ×
1
NA × fve× VLN
× IL2m× PElβ − K βoff × CmElβ − fα × K βαon
× CmElβ × PElα + K βαoff × TmEl − Kin × CmElβ (C6)
dTmEl
dt
= fβ × K αβon × CmElα × PElβ − K αβoff × TmEl
+ fα × K βαon × CmElβ × PElα − K βαoff × TmEl
− Kin × TmEl (C7)
dCElα
dt
= K αon ×
1
NA × fve× VLN × IL2× P
El
α − K αoff
× CElα − K αβon × CElα × PElβ + K αβoff × T El
+ (1− Nα)×
(
− 1
NA × fve× VLN K
Ab
on
×CElα × Ab+ K Aboff × CAbElα
)
(C8)
dCElβ
dt
= K βon ×
1
NA × fve× VLN × IL2× P
El
β − K βoff
× CElβ − K βαon × CElβ × PElα + K βαoff × T El
+ (1− Nβ)×
(
− 1
NA × fve× VLN K
Ab
on
×CElβ × Ab+ K Aboff × CAbElβ
)
− Kin × CElβ (C9)
dT El
dt
= K αβon × CElα × PElβ − K αβoff × T El + K βαon × CElβ
× PElα − K βαoff × T El − Kin × T El (C10)
dCAbElα
dt
= (1− Nα)×
(
K αon ×
1
NA × fve× VLN × IL2
Ab
× PElα − K αoff × CAbElα
)
+ (1− Nα)
×
(
1
NA × fve× VLN K
Ab
on × CElα × Ab
−K Aboff × CAbElα
)
(C11)
dCAbElβ
dt
= (1− Nβ)×
(
K βon ×
1
NA × fve× VLN
×IL2Ab × PElβ − K βoff × CAbElβ
)
+ (1− Nβ)
×
(
1
NA × fve× VLN K
Ab
on × CElβ × Ab
−K Aboff × CAbElβ
)
− Kin × CAbElβ (C12)
PElα = RaEl − CElα − CAbElα − T El − CmElα − TmEl ,
PElβ = RbEl − CElβ − CAbElβ − T El − CmElβ − TmEl (C13)
SigE = CEAβ + T EA + CmEAβ + TmEA + CAbEAβ + ilαEA ,
SigR = CRAβ + T RA + CmRAβ + TmRA + CAbRAβ , (C14)
SigM = CMAβ + T MA + CmMAβ + TmMA + CAbMAβ + ilαMA
The dynamics of the number of IL2 (IL2), IL2 mutants (IL2m),
mAbs (Ab), and immune-complexes (IL2Ab) in the lymph node is
modeled using Eqs C1 and C4; while the dynamics of the num-
ber of IL2-IL2R complexes (CEα , C
E
β , T
E); IL2m-IL2R complexes
(CmEα, Cm
E
β , Tm
E); and IL2-IL2R-mAbs complexes CAbEα, CAb
E
β
per cell are modeled following equations (22–24); (19–21); and
(25, 26), respectively. Note that, to simplify, we only present here
the equations corresponding to the IL2 and IL2m complexes
formed at the E cell membrane. Equivalent equations are writ-
ten for R and M cells. Algebraic relations are provided in Eqs C13
and C14, for the amount of free alpha (PEα ) and beta chains (P
E
β )
of the IL2 receptor per E cell, and the mean number of bound
cytokines signaling receptors per activated E (SigE), R (SigR), and
M (SigM) cell. Note that, the terms SigE, SigR, and SigM in Eq. C14
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are the one used in the equations for the dynamics of T cells, related
with the process of cells receiving cytokine derived signals from
IL2 or alternative cytokines (see section 1.2). The variables and
parameters used in Ref. (15–28) are defined in Tables 1–3.
In Eqs C1, C3, and C4, the first and second terms cor-
respond to the processes of dissociation and formation of
immune-complexes. Additionally, due to the presence of T cells
in the Lymph Node, we consider in these equations the dissoci-
ation and association processes of IL2 and IL2-mAb complexes
with the alpha or beta IL2R chains in the cell membranes. In
this sense, is taken into account the increase in the amount of
free IL2, IL2m, and immune-complexes, due to the dissociation
process of IL2-IL2R, IL2m-IL2R, and IL2-mAb-IL2R complexes
respectively (third terms in Eqs C1 and C4 and second term in
Eq. C2). On the other hand, the association of free IL2, IL2m,
and immune-complexes to free alpha or beta IL2R chains is con-
sidered to increase the amount of IL2-IL2R and IL2-mAb-IL2R
complexes (fourth terms in Eqs C1 and C4, third term in Eq.
C2). Additionally, is modeled the processes where mAbs can be
dissociated from IL2-mAb-IL2R complexes, increasing the num-
ber of free mAbs (third terms in Eq. C3); and the process where
free mAbs associate to IL2-IL2R complexes in the cell membrane
(fourth terms in Eq. C3). The symbolic labels l and j, appear-
ing in the equations (15–18), denote respectively the functional
state of the cell (l=N : resting, l=A: activated, l=C : cycling) and
the different IL2R chains (j= α alpha chain and j= β beta dimer
chain). Finally, the production of IL2 endogenous by activated E
cells, which can be inhibited during cell activation by the pres-
ence of R cells co-conjugated in the same APC, is considered to
increase the amount of this cytokine in the Lymph Node (last term
in Eq. C1). The properties of different IL2m is controlled in the
model by the parameters fα and fβ which multiply the association
of constant of this molecules to the alpha and beta chain of the
IL2 receptor.
The formation of high affinity IL2-IL2R and IL2m-IL2R com-
plexes in a cell membrane is modeled as a two-step process, using
equations (22–24) and (19–21) respectively. Firstly, free IL2 or
IL2m binds to the available free alpha or beta chains of the
IL2R, forming the intermediate or low affinity IL2-IL2R complexes
respectively (first terms in Eqs C8, C9 and C5, C6), as mentioned
above for the dynamics of IL2. By the corresponding dissociation
process are recovered free molecules and receptor chains (second
term in Eqs C8, C9 and C5, C6). The association process of inter-
mediate or low affinity IL2-IL2R complexes with the remaining
IL2 receptor chain, leads to the formation of high affinity IL2-
IL2R complexes (third term in Eqs C8, C9 and C5, C6), and first
and third terms in Eqs C10 and C7. The dissociation of these com-
plexes is modeled in the fourth term in Eqs C9, C10 and C5, C6
and second and fourth terms in Eqs C10 and C7. The internaliza-
tion of IL2 and IL2m forming complexes with IL2Rs is modeled
considering that it only occurs for signaling IL2-IL2R complexes
requiring binding to the beta chain (last term in Eqs C9, C10 and
C6, C7).
The formation of IL2-mAb-IL2R complexes in the cell mem-
brane is modeled in Eqs C11 and C12, and in the fifth term in
Eqs C8 and C9. In this sense, we consider the association and dis-
sociation processes of free immune-complexes with the alpha or
beta IL2R chains (first term in Eqs C11 and C12); and the same
processes for free mAbs with IL2-IL2R complexes in the cell mem-
brane (fifth term in Eqs C8 and C9); second term in Eqs C11 and
C12). The possibility of formation of intermediate or low affin-
ity IL2-mAb-IL2R complexes depend on the IL2 interface that
mAbs recognize (controlled in simulations by the parameter Nj,
see Table 3). We don’t consider the formation of high affinity IL2-
mAb-IL2R complexes, due to association of antibodies with the
high affinity IL2-IL2R complexes or the association of intermedi-
ate or low affinity IL2-mAb-IL2R complexes with the remaining
IL2 receptor chain, because we are studying mAbs that bind to the
alpha or beta interface of the IL2 which will block the formation
of these complexes. Finally, the internalization of IL2 as immune-
complexes bound to the beta chains of IL2Rs in the cell membrane
is also modeled (last term in Eq. C12).
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